

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12552-002001	Application No. 09/184,572
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant McKerracher et al.	
		Filing Date November 2, 1998	Group Art Unit 1647



**U.S. Patent Documents**


Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AC							
	AD							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AE	Barinaga (1994) "Old Protein Provides New Clue To Nerve Regeneration Puzzle", Science 265:1800-1801
	AF	Bartsch et al., (1995) "Lack of Evidence That Myelin-Associated Glycoprotein is a Major Inhibitor of Axonal Regeneration in the CNS" Neuron 15:1375-1381
	AG	Caroni et al., (1988) "Antibody against Myelin-Associated Inhibitor of Neurite Growth Neutralizes Nonpermissive Substrate Properties of CNS White Matter" Neuron, 1:85-96
	AH	Caroni et al (1988) "Two Membrane Protein Fractions from Rat Central Myelin with Inhibitory Properties for Neurite Growth and Fibroblast Spreading" J. Cell Biol. 106:1281-1288
	AI	Daniels et al., (1998) "Membrane targeting of p21-activated kinase 1 (PAK1) induces neurite outgrowth from PC12 cells" EMBO Journal 17(3):754-764
	AJ	David et al., (1995) "Laminin Overrides the Inhibitory Effects of Peripheral Nervous System and Central Nervous System Myelin-Derived Inhibitors of Neurite Growth", J. Neuro. Res. 42:594-602
	AK	Lehman et al., (1999) "Inactivation of Rho Signaling Pathway Promotes CNS Axon Regeneration" J. Neurosci. 19(17):7537-7547
	AL	McKerracher et al., (1994) "Identification of Myelin-Associated Glycoprotein as Major Myelin-Derived Inhibitor of Neurite Growth", Neuron 13:805-811
	AM	Rubin et al., (1995) "Inhibition of PC12 Cell Attachment and Neurite Outgrowth by Detergent Solubilized CNS Myelin Proteins" Euro. J. Neurosci. 7:2524-2529
	AN	Schwab et al., (1994) "Inhibitory influences" Nature 371:658-659
	AO	Tomaselli et al., (1990) "A Neuronal Cell Line (PC12) Expresses Two $\beta_1$ -Class Integrins-- $\alpha_1\beta_1$ and $\alpha_3\beta_1$ —That Recognize Different Neurite Outgrowth-Promoting Domains in Laminin" Neuron 5:651-662

Examiner Signature 	Date Considered 8-5-04
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
12552-002001Application No.  
09/184,572**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

Applicant  
McKerracher et al.Filing Date  
November 2, 1998Group Art Unit  
1647

(37 CFR 1.98(b))

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>SC</i>	AA	6,218,410 B1	04/17/2001	Uehata et al.			
<i>SC</i>	AB	6,451,825 B1	09/12/2002	Uehata et al.			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

JUN 06 2003

TECH CENTER 1600/2900

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
<i>SC</i>	AL	2,263,425	02/19/1998	Canada				
	AM							
	AN							
	AO							
	AP							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AQ	
	AR	
	AS	
	AT	

Examiner Signature

*Scum*

Date Considered

8-9-04

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.